Illumina News

's stock had its "positive" rating reaffirmed by research analysts at Bank of America in a report released on Wednesday, Analyst Ratings Network.com reports.

Don't waste time trying to figure it out for yourself; tip the scales in your favor and add our experience to your team.

Personalis announced today that it has successfully completed Illumina CSPro certification for sequencing on HiSeq and MiSeq, gaining entry to an elite group of Illumina genomics service providers globally.

As biotechnology investors, we often spend countless hours considering the next cure for cancer and many other advancements most often made by pharmaceutical companies.

Illumina, Inc. today announced that Verinata Health, an Illumina company, has published the first peer-reviewed study of non-invasive prenatal test performance in a clinical laboratory setting.

On April 22, after the close of trading, Illumina released its Q1 2013 earnings, delivering another solid quarter in the face of perceived uncertainty.

The firm currently has a "neutral" rating on the stock. A number of other firms have also recently commented on ILMN.

Netflix, Inc. has released its earnings report for the first three months of the year, pushing the price per stock up.

There's been plenty of great press -- you might even say hype -- about IBM's "DNA transistor," a new type of gene sequencing technology that had come out of the company's labs.

Illumina Inc. rose the most in almost 15 months after the maker of genetic decoders reported earnings that exceeded analysts' estimates on higher sales.

Dow futures were up 64 points and rising. Nasdaq 100 futures were ahead a strong 18.25 points, while S&P 500 futures rose 6.75 points.

Earlier this year Illumina, the maker of the world's most widely used DNA sequencing machines, agreed to pay nearly half a billion dollars for Verinata, a startup in Redwood City, California, that has hardly any revenues.

Good day, ladies and gentlemen, and welcome to the First Quarter 2013 Illumina Earnings Conference Call.

Illumina, Inc. today announced it has appointed Charles Dadswell as Senior Vice President and General Counsel.

Illumina released its earnings data on Monday. The company reported $0.46 earnings per share for the quarter, beating the analysts' consensus estimate of $0.39 by $0.07, StocKRatingsNetwork.com reports.

GAAP net loss for the quarter of $23 million, or $0.18 per diluted share due to a charge of $106.9 million related to the Syntrix Biosystems, Inc.